Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Bloomfield

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Reply to S. Gulia et alPaul DiSilvestro, Elizabeth S Lowe, Ralph Bloomfield
International Journal of Psychiatry in Clinical Practice|September 9, 2014
Stress levels experienced by parents of children with and without attention-deficit/hyperactivity disorder during the back-to-school period: results of a European and Canadian surveyIsabel Hernández-Otero, Lakshman Doddamani, Benoit Dutray, et al.
The American Journal of Gastroenterology|March 18, 2010
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial dataStefan Schreiber, Jean-Frédéric Colombel, Ralph Bloomfield, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 6, 2010
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 StudyWilliam J Sandborn, Stefan Schreiber, Stephen B Hanauer, et al.
The New England Journal of Medicine|July 20, 2007
Certolizumab pegol for the treatment of Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Simeon Stoinov, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 2, 2010
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 monthsGary R Lichtenstein, Ole Ø Thomsen, Stefan Schreiber, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 28, 2015
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity DisorderTimothy E Wilens, Brigitte Robertson, Vanja Sikirica, et al.
The New England Journal of Medicine|July 20, 2007
Maintenance therapy with certolizumab pegol for Crohn's diseaseStefan Schreiber, Mani Khaliq-Kareemi, Ian C Lawrance, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 3, 2014
Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trialAmaia Hervas, Michael Huss, Mats Johnson, et al.
European Child & Adolescent Psychiatry|May 28, 2013
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trialDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Reply to S. Gulia et alPaul DiSilvestro, Elizabeth S Lowe, Ralph Bloomfield
International Journal of Psychiatry in Clinical Practice|September 9, 2014
Stress levels experienced by parents of children with and without attention-deficit/hyperactivity disorder during the back-to-school period: results of a European and Canadian surveyIsabel Hernández-Otero, Lakshman Doddamani, Benoit Dutray, et al.
The American Journal of Gastroenterology|March 18, 2010
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial dataStefan Schreiber, Jean-Frédéric Colombel, Ralph Bloomfield, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 6, 2010
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 StudyWilliam J Sandborn, Stefan Schreiber, Stephen B Hanauer, et al.
The New England Journal of Medicine|July 20, 2007
Certolizumab pegol for the treatment of Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Simeon Stoinov, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 2, 2010
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 monthsGary R Lichtenstein, Ole Ø Thomsen, Stefan Schreiber, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 28, 2015
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity DisorderTimothy E Wilens, Brigitte Robertson, Vanja Sikirica, et al.
The New England Journal of Medicine|July 20, 2007
Maintenance therapy with certolizumab pegol for Crohn's diseaseStefan Schreiber, Mani Khaliq-Kareemi, Ian C Lawrance, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 3, 2014
Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trialAmaia Hervas, Michael Huss, Mats Johnson, et al.
European Child & Adolescent Psychiatry|May 28, 2013
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trialDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Pageof 2